Luseogliflozin

Cat. No.:	HY-10449
CAS No.:	898537-18-3
Molecular Formula:	$C_{23}H_{30}O_6S$
Molecular Weight:	434.55
Target:	SGLT
Pathway:	Membrane Transporter/Ion Channel
Storage:	-20°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)



BIOLOGICAL ACTIVITY

Description	Luseogliflozin (TS 071) is a potent, selective, orally active sodium-dependent glucose cotransporter (SGLT) 2 inhibitor, with an IC_{50} of 2.26 nM, about 1765-fold selectivity over SGLT1 (IC_{50}, 3990 nM). Luseogliflozin has the protential for researching type 2 diabetes.	
IC_{50} & Target	SGLT2 2.26 nM (IC_{50})	SGLT1 3990 nM (IC_{50})
In Vitro	Luseogliflozin (TS-071, 3p) is a potent sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor, with an IC_{50} of 2.26 nM, about 1765-fold selectivity over SGLT1 (IC_{50}, 3990 nM); Luseogliflozin has the protential for treating type 2 diabetes[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
In Vivo	Luseogliflozin (1 mg/kg, p.o.) exhibits a blood glucose lowering effect, excellent urinary glucose excretion properties, and promising PK profiles in rats and dogs[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.	

REFERENCES

[1]. Kakinuma H, et al. (1S)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol (TS-071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment. J Med Chem. 2010 Apr 22;53(8):3247-61.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA